Breast cancer affects over 246,000 women and men in the United States each year, with over 40,000 succumbing to the disease yearly. Worldwide, about 519,000 people die from the disease each year.
HER2/neu expressing breast cancer cells have been identified in about one third of patients and are associated with more aggressive tumors, shorter relapse time from treatment and poorer overall survival.
Etubics is developing an immunotherapeutic breast cancer vaccine targeting HER2/neu and other cancer cells targets. Published pre-clinical studies indicate a cell-mediated immune response against HER2/neu which results in reduction of tumor size and control of progression. The immunotherapeutic product has also been shown to prevent tumor establishment in pre-clinical studies.